In a bold effort to confront the twin scourges of opioid and alcohol dependence, Allegheny county is allocating $13.3 million to a two-year clinical trial that will begin in 2027. The project, coordinated by the Center for Addiction, Science, Policy and Research, will enlist 1,200 residents from four distinct sites across the county. Participants will be randomly assigned: half will receive a weekly GLP-1 injection while the other half receives a placebo, all while continuing any existing therapies.
The study’s backbone rests on the expertise of Diana Martínez Heredia, a data scientist with the Allegheny County Department of Human Services, who described the venture as “building on” a growing body of evidence that glucagon-like peptide-1 (GLP-1) agonists can attenuate drug cravings. In her words, “There’s already a lot of research that GLP-1s can help with addiction and we are building on that research.”
Design, scale and scientific oversight
Compared with earlier investigations—one half-year trial that recruited only 88 participants and a nine-week study with fewer than 50 volunteers—this Pittsburgh effort is unprecedented in size. Antoine Douaihy, who heads the addiction medicine program at the University of Pittsburgh’s School of Medicine and UPMC’s Western Psychiatric Hospital, will supervise the four recruitment sites. He noted that “they are small studies” and added that “their designs are methodologically not very strong.” By contrast, the new trial’s double-blind, placebo-controlled structure aims to generate robust, generalizable data.
Beyond substance use: employment, housing and public safety
While many prior GLP-1 trials have focused solely on whether participants consume less alcohol or opioids, this study expands the lens to capture downstream outcomes. Martínez Heredia explained, “Most of these trials are looking just at substance use and whether people use less or not.” The partnership with the county’s Department of Human Services allows researchers to merge health records with justice-system data and benefit-program information, offering a “holistic vision of recovery.”
Executive director Nicholas Reville highlighted the broader stakes, stating, “The downstream effects are even larger. The crime, kids being put into foster care, employment loss, tax revenue, incarceration. If you want to really transform society, if you can solve addiction, it would change everything.” In 2025, the county spent nearly $100 million to treat 12,700 individuals with substance-use disorders, underscoring the fiscal urgency.
Patient appeal and potential for replication
Reville also argued that GLP-1 agents may out-perform existing medications because they are “appealing to patients.” He quoted a participant sentiment: “This is the first drug class that people with substance use disorders are eager and excited to take.” The trial’s budget will cover researcher salaries, staff hiring, participant incentives, and the costly medication itself, as Martínez Heredia noted: “A lot of it goes to paying for the medication. It’s a very expensive medication.” If successful, the model could be reproduced elsewhere: “If it works in Pittsburgh, it should work almost everywhere,” Reville concluded.
Oliver Morrison contributed reporting for this story.
